Wender 2004.

Methods	Randomised double‐blind placebo‐controlled trial
Participants	40 healthy postmenopausal women, mean age 55 years, mean time since natural menopause 5 to 7.7 years, mean BMI 26 kg/m2
Interventions	Tibolone 2.5 mg/d Placebo For 1 year
Outcomes	Endometrial thickness, endometrial cancer, uterine bleeding
Notes	Timing: not specified Location: Brasil Single centre
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding of participants and personnel (performance bias) All outcomes	Low risk	page 424: “the tibolone and the placebo tablets and bottles looked identical; the bottles were identified with numbers from 1 to 40. The correspondence between the numbers and the group to which the participant belonged was not disclosed until the end of the study”
Blinding of outcome assessment (detection bias) All outcomes	Low risk	page 424: “all ultrasonographic exams were performed at the Hospital’s Gynecology and Obstetrics Service by the same operator, who was blinded to information concerning participant groups. […] “ The material was analysed twice by 2 pathologists who were also blinded to participant information”
Incomplete outcome data (attrition bias) All outcomes	Low risk	Reasons for withdrawal given: 3 participants/group withdrew from the study Placebo: 1 owing to dizziness, 2 owing to intense climacteric symptoms that did not improve Tibolone: 1 moved to another city, 2 because of missing appointments
Selective reporting (reporting bias)	Unclear risk	Study protocol not available
Conflict of interest	Unclear risk	No details given